Dr Andre Goy Discusses Potential Benefits of Earlier Use of CAR T Therapies – AJMC.com Managed Markets Network
stemadminBenefits Of Stem CellsNo comments

Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment. Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed the potential benefits of using CAR T-cell therapies as a second-line treatment. Transcript After the approval of the first CAR T-cell therapies there was a discussion at ASCO about whether these therapies should be used earlier, when they might be more effective.

Read more
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results – StreetInsider.com
stemadminBenefits Of Stem CellsNo comments

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com

Read more
ALERCELL to Attend the Interactive Moneyshow Virtual Expo – Fairfield Sun Times
stemadminBenefits Of Stem CellsNo comments

BOZEMAN, Mont., Oct. 27, 2020 /PRNewswire/ --ALERCELL, INC. ("ALERCELL"), a Biotechnology company specialized in delivering innovative in vitro rapid diagnostic tests, accurate and efficient, to tackle infectious diseases, today announced that Management will make a formal presentation at the Interactive MoneyShow Virtual Expo which will be held virtually on October 27 to 29, 2020.

Read more
Cellular Therapies Move Forward in Lymphomas and Leukemias, But Challenges Remain – OncLive
stemadminBenefits Of Stem CellsNo comments

Great strides have been made with CAR T-cell therapy in different lymphomas and leukemias, which have allowed many patients to achieve durable responses, according to Abhinav Deol, MD, who added that identifying mechanisms of resistance and examining checkpoint inhibitors following relapse on this modality are now active areas of exploration. CAR T-cell therapy is an important modality of treatment; although, prior to therapy, patients must have good performance status and social support. As such, CAR T-cell therapy may not be the best option for every patient, Deol explained

Read more
Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech – Endpoints News
stemadminBenefits Of Stem CellsNo comments

Back in December 2017, as the cell therapy world was still basking in the virtually back-to-back approvals of two pioneering CAR-Ts, researchers at Seattle Childrens Research Institute reported a scientific first in a different corner of the field: engineer B cells to treat disease. The team, led by David Rawlings and Richard James, eventually worked with Longwood Fund to start a biotech around those findings. And now Atlas Venture and RA Capital Management are coming on board to lead a $52 million launch round, joined by Alta Partners, for Be Biopharma.

Read more

Theme: Illdy.